Pfizer logo

Pfizer(PFE)

Leader

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

93
AI Score
Grade A↑ Trending
AI Visibility Score (Beta)
HealthcareEnterprisePFEWebsiteUpdated November 2026

Brand Intelligence Graphcompany

Company Overview

About Pfizer

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Business Model & Competitive Advantage

Pfizer's core commercial portfolio extends across oncology, rare disease, internal medicine, and vaccines. Eliquis (apixaban, co-promoted with Bristol-Myers Squibb) remains the world's best-selling anticoagulant; Ibrance leads in CDK4/6 inhibitor breast cancer therapy; Vyndaqel/Vyndamax dominates the ATTR-CM (transthyretin cardiomyopathy) market where it has achieved blockbuster status. The Prevnar pneumococcal vaccine franchise and Nimenrix meningococcal vaccines anchor a diversified global vaccine portfolio. Pfizer's "Fit-to-Win" restructuring program targets $4 billion in annual cost savings by 2025, realigning R&D investments toward the highest-value pipeline opportunities post-Seagen integration.

Competitive Landscape 2025–2026

In 2025-2026, Pfizer confronts significant patent cliff risks: Eliquis faces generic competition beginning in 2026-2028, representing roughly $7 billion in annual U.S. revenues at risk. The Seagen ADC platform is the primary offense against this cliff, with Padcev already generating $1 billion-plus in annual revenues for metastatic urothelial cancer. Competitive pressures come from AstraZeneca (Enhertu in ADCs), Eli Lilly (oncology expansion), and Merck (Keytruda franchise). Activist investor Starboard Value took a stake in late 2024 and has pressed for more aggressive cost cuts and strategic review. Pfizer's GLP-1 obesity drug danuglipron failed Phase 2 trials in 2023, leaving the company without a direct entry in the fast-growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk.

Founded
1849
Headquarters
Brooklyn, New York, United States
Revenue
$63.6B
Curated content • Fact-checked and verified

The Pfizer Story

Founded in 1849
Brooklyn, New York, United States
Founded by Charles Pfizer, Charles F. Erhart

Founders

Charles PfizerCharles F. Erhart

Recent Activity

View all →
blog_post
C4891035

C4891035 zhoum55 Tue, 11/17/2026 - 01:53 Vepdegestrant (ARV-471) Vepdegestrant (ARV-471) PHASE I Fri, 02/23/2024 - 12:00 Fri, 05/24/2024 - 12:00 NCT06275841 C4891035 Public Disclosure Synopsis .pdf (82.57 KB) N https://clinicaltrials.gov/study/NCT06275841?term=C4891035&viewType=Card&rank=1 C4891035

blog_post
B3461114

B3461114 zhoum55 Wed, 11/04/2026 - 22:40 Vyndamax® / Vyndaqel® Tafamidis (PF-06291826) PHASE I Tue, 02/27/2024 - 12:00 Mon, 05/27/2024 - 12:00 NCT06273839 B3461114 Public Disclosure Synopsis.pdf (90.18 KB) N https://clinicaltrials.gov/study/NCT06273839?term=B3461114&viewType=Card&rank=1 B3461114

blog_post
C4531001

C4531001 zhoum55 Wed, 11/04/2026 - 22:14 PF-07275315 PF-07275315 PHASE I Thu, 06/09/2022 - 12:00 Mon, 05/13/2024 - 12:00 NCT05411588 C4531001 Public Disclosure Synopsis.pdf (317.96 KB) N https://clinicaltrials.gov/study/NCT05411588?term=C4531001&viewType=Card&rank=1 C4531001

blog_post
C4891039

C4891039 zhoum55 Wed, 11/04/2026 - 01:51 Vepdegestrant Vepdegestrant PHASE I Thu, 02/08/2024 - 12:00 Mon, 05/13/2024 - 12:00 NCT06256510 C4891039 Public Disclosure Synopsis.pdf (282.11 KB) N https://clinicaltrials.gov/study/NCT06256510?term=C4891039&viewType=Card&rank=1 C4891039

blog_post
C4521001

C4521001 zhoum55 Wed, 11/04/2026 - 01:24 PF-07264660 PF-07264660 PHASE I Tue, 08/16/2022 - 12:00 Mon, 05/06/2024 - 12:00 NCT05496738 C4521001 Public Disclosure Synopsis_0.pdf (105.4 KB) N https://clinicaltrials.gov/study/NCT05496738?term=C4521001&viewType=Card&rank=1 C4521001

blog_post
A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two PF-07940367 Film-Coated Tablet Formulations Administered as 150 mg Under Fasted Conditions in Healthy Participants

A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two PF-07940367 Film-Coated Tablet Formulations Administered as 150 mg Under Fasted Conditions in Healthy Participants zhoum55 Tue, 11/03/2026 - 03:21 Osivelotor (PF-07940367) Osivelotor (PF-07940367) PHASE I Mon, 01/15/2024 - 12:00 Tue, 05/07/2024 - 12:00 NCT06190561 C5351008 Public Disclosure Synopsis.pdf (101.85 KB) N https://clinicaltrials.gov/study/NCT06190561?term=C5351008&viewType=Card&rank=1 C5351008

10-Q
10-Q — 10-Q

Quarterly Report filed 2026-11-03

8-K
8-K — 8-K

Material Event filed 2026-11-03

8-K
8-K — 8-K

Material Event filed 2026-11-03

blog_post
A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants With Early Stage Duchenne Muscular Dystrophy

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants With Early Stage Duchenne Muscular Dystrophy reddym75 Fri, 10/30/2026 - 06:30 PF-06939926 Fordadistrogene Movaparvovec PHASE II Mon, 08/08/2022 - 12:00 Fri, 10/03/2025 - 12:00 NCT05429372 C3391008 Public Disclosure Synopsis .pdf (123.37 KB) N https://clinicaltrials.gov/study/NCT05429372 C3391008

blog_post
A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) zhoum55 Fri, 10/09/2026 - 05:23 Brentuximab vedotin Brentuximab vedotin PHASE III Thu, 08/20/2020 - 12:00 Fri, 01/23/2026 - 12:00 NCT04404283 C5691003 Public Disclosure Synopsis.pdf (143.34 KB) N https://clinicaltrials.gov/study/NCT04404283?term=C5691003&viewType=Card&rank=1 C5691003 (SGN35-031)

blog_post
A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis

A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis zhoum55 Tue, 09/29/2026 - 03:47 PF-07911145 (VZV modRNA Vaccine) PF-07911145 (VZV modRNA Vaccine) PHASE I Wed, 01/25/2023 - 12:00 Fri, 09/19/2025 - 12:00 NCT05703607 C5031001 SSA Public Disclosure Synopsis.pdf (193.7 KB) N https://clinicaltrials.gov/study/NCT05703607?term=NCT05703607&viewType=Card&rank=1 C5031001 Substudy A

Company Timeline

Major milestones in Pfizer's journey

14
Total Events
6
Acquisitions

Leadership Team

Meet the leaders behind Pfizer

Dr. Albert Bourla

Chairman & Chief Executive Officer

Albert Bourla is a Greek-American veterinarian and businessman who became CEO of Pfizer in January 2019 and Chairman in February 2019. During his 30+ years at Pfizer, he held senior management positions across five countries and established Pfizer's Purpose Blueprint with core values of Courage, Excellence, Equity, and Joy to create a culture where science and people thrive.

David M. Denton

Chief Financial Officer & Executive Vice President

Dave Denton joined Pfizer as CFO and Executive Vice President effective May 2, 2022, providing strategic global financial leadership as a member of Pfizer's Executive Leadership Team. He oversees all financial operations and strategy for the company.

Dr. Chris Boshoff

Chief Scientific Officer & President, Research & Development

Chris Boshoff, M.D., PhD, was appointed Chief Scientific Officer and President of Research & Development effective January 1, 2025, following a comprehensive selection process. Previously Chief Oncology Research and Development Officer, he leads Pfizer's global R&D efforts and scientific strategy.

Aamir Malik

Chief U.S. Commercial Officer & Executive Vice President

Aamir Malik is Executive Vice President and Chief U.S. Commercial Officer, leading the U.S. Commercial business including Primary and Specialty Care Commercial and Medical Affairs, Oncology Commercial, Global Access and Value, and Global Chief Marketing Office organizations as a member of the Executive Leadership Team.

Dr. Andrew Baum

Chief Strategy & Innovation Officer & Executive Vice President

Andrew Baum, M.D., joined Pfizer as Chief Strategy and Innovation Officer and Executive Vice President, reporting to CEO Dr. Albert Bourla. He is a member of Pfizer's Executive Leadership Team responsible for corporate strategy and innovation initiatives.

Key Differentiators

Market Leader

Pfizer is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.

Enterprise Scale

With $63.6B in revenue, Pfizer operates at enterprise scale with proven market validation.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

93
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Moderna logo

Moderna

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép

BNY Mellon logo

BNY Mellon

Consumer Finance
B2cFintechGlobalPublic

BNY Mellon—rebranded as BNY in 2024—is the world's largest custodian bank and a global leader in investment services, tracing its origins to the Bank of New York founded in 1784 by Alexander Hamilton.

Amgen logo

Amgen

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Zocdoc logo

Zocdoc

HealthTech
AnalyticsB2bB2cHealthtechMarketplaceMobile FirstPlatformSaas

Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati

Doximity logo

Doximity

HealthTech
HealthtechSaasB2bB2cStartupPlatformAi PoweredMobile First

Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic

Compare Pfizer with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Pfizer

Claim This Profile

Are you from Pfizer? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.

Claim Pfizer Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Pfizer vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →